Arrowhead Pharmaceuticals, Inc. (ARWR) company profile
Close on Nov 17, 2026Market cap $6.07BP/E –Yield –
About Arrowhead Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
Arrowhead Pharmaceuticals develops RNA interference (RNAi) therapeutics designed to treat severe and intractable diseases by silencing disease-causing genes. The company utilizes its proprietary Targeted RNA Molecule (TRiM) platform to trigger targeted, catalytic gene knockdown across diverse tissue types beyond the liver, including adipose tissue, muscle, pulmonary tissue, and the central nervous system. Arrowhead's primary commercialized product is REDEMPLO (plozasiran), an FDA-approved medicine for adults with familial chylomicronemia syndrome, complemented by a clinical pipeline targeting cardiometabolic, pulmonary, renal, and neurodegenerative disorders. The company serves adult patients suffering from rare and high-prevalence genetic disorders directly and partners with major pharmaceutical companies through licensing and co-development collaborations.
Arrowhead maintains clinical and preclinical drug development programs worldwide, with 18 discovered drug candidates in clinical trials spanning Phase 1 to Phase 3. The company conducts late-stage multi-center clinical trials internationally, holds patent protections across dozens of countries, and is expanding its commercial footprint. The text does not disclose the specific location of the company's corporate headquarters.
Summary of the business section of Arrowhead Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Arrowhead Pharmaceuticals, Inc.
- Founded
- 1989
- Headquarters
- Pasadena, CA
- Address
- 177 E Colorado Blvd, Suite 700 91105
- Phone
- (626) 696-4702
- Website
- arrowheadpharma.com
- Employees
- 711, Sep 30, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- September 30
- Auditor
- KPMG LLP, San Diego, California
Stock & identifiers
- Ticker
- ARWR
- Former tickers
- ARW until Feb 6, 2023
- Exchange
- Nasdaq
- IPO date
- Dec 16, 1993
- Shares outstanding
- 141M, Jul 30, 2026
- Public float
- $1.40B, Mar 31, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 1-for-10 reverse, Nov 17, 2011; 1-for-65 reverse, Jan 15, 2004
- SEC CIK
- 879407
- CUSIP
- 04280A100
- ISIN
- US04280A1007
- FIGI
- BBG000BRVKH0
- Share class FIGI
- BBG001SGT8G5
- LEI
- 549300O3CSB8T7OZ3D66
- EIN
- 46-0408024
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Christopher Richard Anzalone | Chief Executive Officer, Director | 3,798,510 |
| Daniel Joseph Apel | Chief Financial Officer | 172,792 |
| James C. Hamilton | Chief Medical Officer | 226,958 |
| Patrick O'Brien | COO | 472,848 |
| Kenneth Allen Myszkowski | Chief Financial Officer | 465,433 |
| Adeoye Y. Olukotun | Director | 31,600 |
| Michael S. Perry | Director | 111,459 |
| Matthew Gregory Cohen | Director | 11,882 |
| Hongbo Lu | Director | 57,662 |
| Mauro Ferrari | Director | 69,053 |
| William D. Waddill | Director | 56,563 |
| Victoria Vakiener | Director | 37,683 |
| Douglas S. Ingram | Director | 46,215 |
| Douglas B. Given | Director | 136,667 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $9.03M | $42.60M | $2.09M | $80 | $146 |
| FY2024 | $12.42M | -$5.36M | $3.50M | $31 | $94 |
| FY2023 | $9.92M | -$2.17M | $3.15M | $62 | $49 |
| FY2022 | $12.03M | -$40.07M | $4.13M | $77 | $67 |
| FY2021 | $24.70M | $69.06M | $3.32M | $145 | $116 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Christopher Anzalone President and Chief Executive Officer | $981.05K | – | $6.81M | $1.24M | $2.52K | $9.03M | -27% |
| Daniel Apel Chief Financial Officer | $232.21K | $200.00K | $1.29M | $226.41K | $9.29K | $1.75M | – |
| Patrick O’Brien Chief Operating Officer | $653.94K | – | $1.98M | $365.64K | $31.62K | $3.03M | -23% |
| James Hamilton Chief Medical Officer | $617.51K | – | $1.98M | $354.63K | $15.07K | $2.97M | -15% |
| Kenneth Myszkowski Former Chief Financial Officer | $496.78K | – | $1.98M | $155.78K | $28.60K | $2.66M | -25% |
| Tracie Oliver Former Chief Commercial Officer | $43.19K | – | – | – | – | $43.19K | -99% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of September 30, 2025, the Company employed 711 full-time employees based at four facilities in the United States, including Pasadena and San Diego, California, and Madison and Verona, Wisconsin.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?